The many spaces of uPAR: Delivery of theranostic agents and nanobins to multiple tumor compartments through a single target

Theranostics

Volumn 3, Issue 7, 2013, Pages 496-506

  O'Halloran, Thomas V ^a,b   Ahn, Richard ^b   Hankins, Patrick ^b   Swindell, Elden ^c   Mazar, Andrew P ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Northwestern University   (United States)

Author keywords

Nanobins; Theranostics; Urokinase plasminogen activator

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GROWTH FACTOR TETRAXETAN BI 213; IRON OXIDE; NANOPARTICLE; PSEUDOMONAS EXOTOXIN; TETRAXETAN CU 68; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR;

ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL POPULATION; CELL PROLIFERATION; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DRUG TRANSPORT; HUMAN; IC 50; LUNG NON SMALL CELL CANCER; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; STOMACH CANCER;

EID: 84883161960     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.4953     Document Type: Review

References (77)

1. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002; 3: 932-43.
2. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev. 2008; 34: 122-36. doi:S0305-7372(07)00181-8 [pii]10.1016/j.ctrv.2007.10.005.
3. Mazar AP. Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res. 2008; 14: 5649-55.
4. Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost. 2007; 97: 336-42.
5. Hildenbrand R, Gandhari M, Stroebel P, Marx A, Allgayer H, Arens N. The urokinase-system--role of cell proliferation and apoptosis. Histol Histopathol. 2008; 23: 227-36.
6. Mekkawy AH, Morris DL, Pourgholami MH. Urokinase plasminogen activator system as a potential target for cancer therapy. Future Oncol. 2009; 5: 1487-99.
7. Eden G, Archinti M, Furlan F, Murphy R, Degryse B. The urokinase receptor interactome. Curr Pharm Des. 2011; 17: 1874-89.
8. Mazar AP, Ahn RW, O'Halloran TV. Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic. Curr Pharm Des. 2011; 17: 1970-8.
9. Goldstein LJ, Stemmer SM, Schmalfeldt B, Gottschalk N, Cardoso F, Dushkin H, et al. Phase II, two-arm, double-blind, multicenter, randomized study of the combination of oral WX-671 plus capecitabine versus capecitabine in first-line HER2-negative metastatic breast cancer (MBC). J Clin Oncol. 2010; 28 (Suppl 15s): abstrTPS131.
10. Heinemann V, Ebert MP, Pinter T, Bevan P, Neville NG, Mala C. Randomized phase II trial with an uPA inhibitor (WX-671) in patients with locally advanced nonmetastatic pancreatic cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010; 28.
11. Wilex. MESUPRON® met its primary objective of demonstrating efficacy in the proof of concept phase II breast cancer trial. 2012.
12. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene. 2000; 19: 6642-50. doi:10.1038/sj.onc.1204097.
13. Noel A, Gutierrez-Fernandez A, Sounni NE, Behrendt N, Maquoi E, Lund IK, et al. New and paradoxical roles of matrix metalloproteinases in the tumor microenvironment. Frontiers in pharmacology. 2012; 3: 140. doi:10.3389/fphar.2012.00140.
14. Baramova EN, Bajou K, Remacle A, L'Hoir C, Krell HW, Weidle UH, et al. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Letters. 1997; 405: 157-62. doi:10.1016/s0014-5793(97)00175-0.
15. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell. 1997; 91: 439-42.
16. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003; 3: 362-74. doi:10.1038/nrc1075.
17. Ellis V, Behrendt N, Dano K. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem. 1991; 266: 12752-8.
18. Kugler MC, Wei Y, Chapman HA. Urokinase receptor and integrin interactions. Curr Pharm Des. 2003; 9: 1565-74.
19. Tarui T, Mazar AP, Cines DB, Takada Y. Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction. J Biol Chem. 2001; 276: 3983-90. doi:10.1074/jbc.M008220200.
20. Hu J, Jo M, Cavenee WK, Furnari F, VandenBerg SR, Gonias SL. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. Proc Natl Acad Sci U S A. 2011; 108: 15984-9. doi:10.1073/pnas.1113416108.
21. Furlan F, Orlando S, Laudanna C, Resnati M, Basso V, Blasi F, et al. The soluble D2D3(88-274) fragment of the urokinase receptor inhibits monocyte chemotaxis and integrin-dependent cell adhesion. J Cell Sci. 2004; 117: 2909-16. doi:10.1242/jcs.01149.
22. Webb DJ, Nguyen DH, Gonias SL. Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and matrigel invasion. J Cell Sci. 2000; 113 ( Pt 1): 123-34.
23. Huai Q, Mazar AP, Kuo A, Parry GC, Shaw DE, Callahan J, Li Y, Yuan C, Bian C, Chen L, Furie B, Furie BC, Cines DB, Huang M. Structure of human urokinase plasminogen activator in complex with its receptor. Science. 2006;311: 656-9.
24. Degryse B. The Urokinase Receptor and Integrins Constitute a Cell Migration Signalosome The Cancer Degradome. In: Edwards D, Høyer-Hansen G, Blasi F, Sloane BF, editors.: Springer New York; 2008;: 451-74.
25. Monaghan-Benson E, McKeown-Longo PJ. Urokinase-type plasminogen activator receptor regulates a novel pathway of fibronectin matrix assembly requiring Src-dependent transactivation of epidermal growth factor receptor. J Biol Chem. 2006; 281: 9450-9. doi:10.1074/jbc.M501901200.
26. Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol. 2006;18: 516-23.
27. Hutchinson J, Jin J, Cardiff RD, Woodgett JR, Muller WJ. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol. 2001; 21: 2203-12.
28. Nykjaer A, Conese M, Christensen EI, Olson D, Cremona O, Gliemann J, et al. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. Embo J. 1997; 16: 2610-20. doi:10.1093/emboj/16.10.2610.
29. Bene MC, Castoldi G, Knapp W, Rigolin GM, Escribano L, Lemez P, et al. CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review. Leukemia. 2004; 18: 394-400. doi:10.1038/sj.leu.2403250.
30. Hjertner O, Qvigstad G, Hjorth-Hansen H, Seidel C, Woodliff J, Epstein J, et al. Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells. Br J Haematol. 2000; 109: 815-22.
31. Bhuvarahamurthy V, Schroeder J, Denkert C, Kristiansen G, Schnorr D, Loening SA, et al. In situ gene expression of urokinase-type plasminogenactivator and its receptor in transitional cell carcinoma of the human bladder. Oncol Rep. 2004; 12: 909-13.
32. Cantero D, Friess H, Deflorin J, Zimmermann A, Brundler MA, Riesle E, et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer. 1997; 75: 388-95.
33. Giannopoulou I, Mylona E, Kapranou A, Mavrommatis J, Markaki S, Zoumbouli C, et al. The prognostic value of the topographic distribution of uPAR expression in invasive breast carcinomas. Cancer Lett. 2007; 246: 262-7.
34. Kenny HA, Leonhardt P, Ladanyi A, Yamada SD, Montag A, Im HK, et al. Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res. 2011; 17: 459-71. doi:1078-0432.CCR-10-2258 [pii]10.1158/1078-0432.CCR-10-2258.
35. Li Y, Cozzi PJ. Targeting uPA/uPAR in prostate cancer. Cancer Treat Rev. 2007; 33: 521-7. doi:10.1016/j.ctrv.2007.06.003.
36. Li Z-B, Niu G, Wang H, He L, Yang L, Ploug M, et al. Imaging of Urokinase-Type Plasminogen Activator Receptor Expression Using a 64Cu-Labeled Linear Peptide Antagonist by microPET. Clin Cancer Res. 2008; 14: 4758-66.
37. Pyke C, Ralfkiaer E, Ronne E, Hoyer-Hansen G, Kirkeby L, Dano K. Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology. 1994; 24: 131-8.
38. Sullivan R, Graham CH. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev. 2007; 26: 319-31. doi:10.1007/s10555-007-9062-2.
39. Gutova M, Najbauer J, Gevorgyan A, Metz MZ, Weng Y, Shih CC, et al. Identification of uPAR-positive chemoresistant cells in small cell lung cancer. PLoS One. 2007; 2: e243. doi:10.1371/journal.pone.0000243.
40. Jo M, Eastman BM, Webb DL, Stoletov K, Klemke R, Gonias SL. Cell signaling by urokinase-type plasminogen activator receptor induces stem cell-like properties in breast cancer cells. Cancer Res. 2010; 70: 8948-58. doi:10.1158/0008-5472.CAN-10-1936.
41. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, et al. Acquisition of Epithelial-Mesenchymal Transition Phenotype of Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch Signaling Pathway. Cancer Res. 2009; 69: 2400-7. doi:10.1158/0008-5472.can-08-4312.
42. Yang L, Peng XH, Wang YA, Wang X, Cao Z, Ni C, et al. Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin Cancer Res. 2009; 15: 4722-32. doi:10.1158/1078-0432.CCR-08-3289.
43. Cortes-Dericks L, Carboni GL, Schmid RA, Karoubi G. Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed. Int J Oncol. 2010; 37: 437-44.
44. Yang L, Avila H, Wang H, Trevino J, Gallick GE, Kitadai Y, et al. Plasticity in Urokinase-Type Plasminogen Activator Receptor (uPAR) Display in Colon Cancer Yields Metastable Subpopulations Oscillating in Cell Surface uPAR Density,ÄîImplications in Tumor Progression. Cancer Res. 2006; 66: 7957-67. doi:10.1158/0008-5472.can-05-3208.
45. Bin Hafeez B, Adhami VM, Asim M, Siddiqui IA, Bhat KM, Zhong W, et al. Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Clin Cancer Res. 2009; 15: 452-9. doi:10.1158/1078-0432.CCR-08-1631.
46. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol. 2010; 11: 23-36.
47. Heiss MM, Allgayer H, Gruetzner KU, Funke I, Babic R, Jauch KW, et al. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med. 1995; 1: 1035-9.
48. Meng S, Tripathy D, Shete S, Ashfaq R, Saboorian H, Haley B, et al. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci U S A. 2006; 103: 17361-5. doi:10.1073/pnas.0608113103.
49. Braun S, Schlimok G, Heumos I, Schaller G, Riethdorf L, Riethmuller G, et al. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res. 2001; 61: 1890-5.
50. Li C, Cao S, Liu Z, Ye X, Chen L, Meng S. RNAi-mediated downregulation of uPAR synergizes with targeting of HER2 through the ERK pathway in breast cancer cells. International journal of cancer Journal international du cancer. 2010; 127: 1507-16. doi:10.1002/ijc.25159.
51. Weickhardt AJ, Price TJ, Chong G, Gebski V, Pavlakis N, Johns TG, et al. Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer. Journal of Clinical Oncology. 2012; 30: 1505-12. doi:10.1200/jco.2011.38.6599.
52. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer. Journal of Clinical Oncology. 2010; 28: 1124-30. doi:10.1200/jco.2008.21.4437.
53. Knor S, Sato S, Huber T, Morgenstern A, Bruchertseifer F, Schmitt M, et al. Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer. Eur J Nucl Med Mol Imaging. 2008; 35: 53-64. doi:10.1007/s00259-007-0582-3.
54. Persson M, Madsen J, Ostergaard S, Jensen MM, Jorgensen JT, Juhl K, et al. Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion. J Nucl Med. 2012; 53: 138-45. doi:10.2967/jnumed.110.083386.
55. Duffy MJ, O'Donovan N, Crown J. Use of molecular markers for predicting therapy response in cancer patients. Cancer Treat Rev. 2011; 37: 151-9. doi:10.1016/j.ctrv.2010.07.004.
56. Mazar AP, Buko A, Petros AM, Barnathan ES, Henkin J. Domain analysis of urokinase plasminogen activator (u-PA): Preparation and characterization of intact A-chain molecules. Fibrinolysis. 1992; 1: 49-55. doi:10.1016/0268-9499(92)90094-x.
57. Rajagopal V, Kreitman RJ. Recombinant toxins that bind to the urokinase receptor are cytotoxic without requiring binding to the alpha(2)-macroglobulin receptor. J Biol Chem. 2000; 275: 7566-73.
58. Kounnas MZ, Morris RE, Thompson MR, FitzGerald DJ, Strickland DK, Saelinger CB. The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J Biol Chem. 1992; 267:12420-3.
59. Hall WA, Vallera DA. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme. Neurosurg Focus. 2006; 20: E23. doi:10.3171/foc.2006.20.4.15.
60. Huang J, Li YM, Massague J, Sicheneder A, Vallera DA, Hall WA. Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer. J Neurooncol. 2012; doi:10.1007/s11060-012-0904-6.
61. Abdalla MO, Karna P, Sajja HK, Mao H, Yates C, Turner T, et al. Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy. J Control Release. 2011; 149: 314-22. doi:10.1016/j.jconrel.2010.10.030.
62. Huang X, Peng X, Wang Y, Wang Y, Shin DM, El-Sayed MA, et al. A Reexamination of Active and Passive Tumor Targeting by Using Rod-Shaped Gold Nanocrystals and Covalently Conjugated Peptide Ligands. ACS Nano. 2010; 4: 5887-96. doi:10.1021/nn102055s.
63. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006; 66: 6732-40. doi:10.1158/0008-5472.CAN-05-4199.
64. Wang M, Loãàwik DWPM, Miller AD, Thanou M. Targeting the Urokinase Plasminogen Activator Receptor with Synthetic Self-Assembly Nanoparticles. Bioconjugate Chemistry. 2008; 20: 32-40. doi:10.1021/bc8001908.
65. Lin L, Gardsvoll H, Huai Q, Huang M, Ploug M. Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy. J Biol Chem. 2010; 285: 10982-92. doi:10.1074/jbc.M109.093492.
66. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science (New York, NY. 2004; 303: 1818-22.
67. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nano. 2007; 2: 751-60.
68. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65: 271-84. doi:10.1016/s0168-3659(99)00248-5.
69. Ahn RW, Chen F, Chen H, Stern ST, Clogston JD, Patri AK, et al. A Novel Nanoparticulate Formulation of Arsenic Trioxide with Enhanced Therapeutic Efficacy in a Murine Model of Breast Cancer. Clin Cancer Res. 2010; 16: 3607-17. doi:10.1158/1078-0432.ccr-10-0068.
70. Chen H, Pazicni S, Krett NL, Ahn RW, Penner-Hahn JE, Rosen ST, et al. Coencapsulation of Arsenic- and Platinum-based Drugs for Targeted Cancer Treatment. Angew Chem Int Ed. 2009; 121: 9459-63.
71. Lee S-M, Chen H, Dettmer CM, O'Halloran TV, Nguyen ST. Polymer-caged liposomes: a pH-responsive delivery system with high stability. J Am Chem Soc. 2007; 129: 15096-7.
72. Lee S-M, Ahn RW, Chen F, Fought AJ, O'Halloran TV, Cryns VL, et al. Biological evaluation of pH-responsive polymer-caged nanobins for breast cancer therapy. ACS Nano. 2010; 4: 4971-8. doi:10.1021/nn100560p.
73. Lee S-M, O'Halloran TV, Nguyen ST. Polymer-Caged Nanobins for Synergistic Cisplatin-Doxorubicin Combination Chemotherapy. J Am Chem Soc. 2010. doi:10.1021/ja107333g.
74. Levenson RM. Spectral imaging perspective on cytomics. Cytometry A. 2006; 69: 592-600. doi:10.1002/cyto.a.20292.
75. Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB, Boyd DD, Mazar AP, Ellis LM. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res. 2005; 65: 7775-81.
76. Van Buren G, Gray MJ, Dallas NA, Xia L, Lim SJ, Fan F, Mazar AP, Ellis LM. Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver. Cancer. 2009;115: 3360-8. doi: 10.1002/cncr.24371.
77. Rabbani SA, Ateeq B, Arakelian A, Valentino ML, Shaw DE, Dauffenbach LM, Kerfoot CA, Mazar AP. An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo. Neoplasia 2010; 12: 778-88.